# Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

> **NCT06641024** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia, in Relapse
- Refractory Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** MC-1-50

## Key facts

- **NCT ID:** NCT06641024
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2027-11-01
- **Final completion:** 2039-11-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06641024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06641024, "Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06641024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*